

In ~~the~~ Reissue Application of:

Lucas-Laskey et al.

Application No.: 10/721,020

Original Patent No. 5,760,069

Original Issue Date: June 2, 1998

Reissue Filed: November 25, 2003

For: METHOD OF TREATMENT FOR
DECREASING MORTALITY
RESULTING FROM CONGESTIVE
HEART FAILURE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the information on the attached listing. This Supplemental Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Supplemental Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form. Copies of the listed non-patent literature documents are attached.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.




By: _____

Mark J. Feldstein
Reg. No. 46,693

Dated: March 10, 2006

IDS Form PTO/SB/08: Substitute for form 1449A/PTO <div style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div style="text-align: center; font-size: small;">(Use as many sheets as necessary)</div>			Complete if Known		
			<i>Application Number</i>	10/721,020	
			<i>Filing Date</i>	November 25, 2003	
			<i>First Named Inventor</i>	Lucas-Laskey et al.	
			<i>Art Unit</i>	1614	
			<i>Examiner Name</i>	K. Weddington	
			<i>Attorney Docket Number</i>	04012.0385-00000	
Sheet	1	of	1		



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials ⁷	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials ⁷	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ⁷	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
	1	<i>Bristol Meyers Squibb v. Ben Venue Labs.</i> , 246 F.3d 1368 (Fed. Cir. 2001).	
	2	<i>Rapoport v. Dement</i> , 254 F.3d 1053 (Fed. Cir. 2001).	
	3	<i>Jansen v. Rexall Sundown, Inc.</i> , 342 F.3d 1329, 1333-34 (Fed. Cir. 2003).	
	4	<i>Glaxo Group Ltd. v. Teva Pharma, Inc.</i> , 2004 U.S. Dist. LEXIS 16750, at *56-57 (D. Del. 2004).	

Examiner Signature	Date Considered	
--------------------	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.